New inhaled drug for lung scarring enters early human testing
NCT ID NCT07344558
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial is testing an inhaled form of nintedanib (called MNKD-201) in 24 people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs. The study aims to see if the drug is safe and tolerable when breathed in, and how the body processes it. Participants will receive either the inhaled drug or a placebo, and researchers will monitor for side effects like wheezing or chest tightness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nintedanib dry powder for inhalation
What this could lead to
If successful, this could lead to a new, inhaled form of nintedanib that may be easier for IPF patients to take than the current oral pill.
What could go wrong
This is a very early, small Phase 1b trial with only 24 people, focused on safety and dosing. It is not designed to prove the drug works, and side effects like bronchospasm are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Innova Pharma Research
RECRUITINGDoral, Florida, 33172, United States
Contact
Contact Email: •••••@•••••
-
Low Country Research
RECRUITINGCharleston, South Carolina, 29406, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Metroplex Pulmomary & Sleep Center
RECRUITINGMcKinney, Texas, 75069, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
New Access Research and Medical Services
RECRUITINGMiami, Florida, 33186, United States
Contact
Contact Email: •••••@•••••
-
New Life Medical Research
RECRUITINGHialeah, Florida, 33012, United States
Contact
Contact Email: •••••@•••••
-
Palmtree Clinical Research
RECRUITINGPalm Springs, California, 92262, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Pulmonary Medicine Consultants
RECRUITINGMcKinney, Texas, 75071, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Southeastern Research Center
RECRUITINGWinston-Salem, North Carolina, 27103, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
VALDI
RECRUITINGFresno, California, 93720, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact